Health Care·Pharmaceuticals·$183.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.95 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.95 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the challenges in the current market environment. They emphasized their commitment to innovation and maintaining a strong pipeline.
Management did not provide specific guidance for the upcoming quarters.
The company remains focused on its long-term growth strategy.
This earnings report indicates that Novo Nordisk did not meet expectations on EPS, but specific revenue figures were not disclosed. The lack of guidance may leave investors uncertain about the company's future performance. The stock reaction is currently unavailable, reflecting market uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HARTFORD INS GROUP I
Apr 29, 2013